COVID-19 trials registries data warehouse

http://en.irct.ir/trial/59923

Dr Majid Ghayour Mobarhan

GhayourM@mums.ac.ir

2021-11-29

Completed

RCT

Randomized

Parallel

Open label

single-center

Treatment

The patient has received remdesivir and corticosteroids and antibiotics and anticoagulants At least one day and at most 5 days have passed since the patient's hospitalization. O2 saturation for 10 minutes without oxygen is less than 89 and more than 75 Age between 18 to 75 year Does not have a history of G6PD Deficiency Absence of chronic renal failure with GFR <30 Absence of heart failure with EF<40% Does not have COPD with CO2>45 The patient is not intubated Does not have systolic Blood Pressure <90 Do not take SSRI, MAO Inhibitor drugs Has not received plasma therapy, IVIG, hemoperfusion, Tocilizumab and plasmapheresis before administration of methylene blue Does not be pregnant The patient should be conscious

Patient dissatisfaction History of allergy or gastrointestinal intolerance to methylene blue

2

Mashhad University of Medical Sciences

18

75

Iran

Severe disease at enrollment

6: Severe disease at enrollment

130

mortality

Phase 3

[{"arm_notes": "", "treatment_id": 797, "treatment_name": "Methylene blue", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]